Strategic funding momentum Recent Series B closure with a Myeloma Investment Fund commitment signals credible external validation and momentum in Nammi’s lead program. This creates openings for co-development, out-licensing, or milestone-driven partnerships with pharma players seeking to back early-stage IO assets in myeloma and CD138-directed mechanisms.

Localized IO edge Nammi’s Masked Immunocytokine approach concentrates immune activation in the tumor microenvironment, reducing systemic exposure. This safer, combinable IO modality is attractive for partners aiming to accelerate or de-risk combination strategies with checkpoint inhibitors or other modulators.

Lead program potential Lead candidate QXL138AM targets CD138 and is positioned for first-in-human testing, offering a clear hook for alliances with myeloma-focused developers and CD138-related assets. Early-stage collaboration discussions could cover trial support, biomarker strategy, and shared development plans.

Nammisome platform value Nammisome, Nammi’s immunomodulatory prodrug nanoparticle platform, provides a modular delivery framework that can enable targeted IO therapies. Potential customers include pharma companies seeking safer systemic profiles or novel delivery of prodrugs in solid tumors and hematologic malignancies.

Financial and partnering traction With a lean team, modest revenue and active fundraising, Nammi presents a compelling opportunity for strategic deals, CRO/CDMO collaborations, and manufacturing partnerships to accelerate preclinical and early clinical development and move toward scalable production.